Cancer review: Cholangiocarcinoma
Open Access
- 1 January 2015
- journal article
- review article
- Published by Medknow in Journal of Carcinogenesis
- Vol. 14 (1), 1
- https://doi.org/10.4103/1477-3163.151940
Abstract
Cholangiocarcinoma (CCA) is the most common biliary tract malignancy. CCA is classified as intrahepatic, perihilar or distal extrahepatic; the individual subtypes differ in their biologic behavior, clinical presentation, and management. Throughout the last decades, CCA incidence rates had significantly increased. In addition to known established risk factors, novel possible risk factors (i.e. obesity, hepatitis C virus) have been identified that are of high importance in developed countries where CCA prevalence rates have been low. CCA tends to develop on the background of inflammation and cholestasis. In recent years, our understanding of the molecular mechanisms of cholangiocarcinogenesis has increased, thereby, providing the basis for molecularly targeted therapies. In its diagnostic evaluation, imaging techniques have improved, and the role of complementary techniques has been defined. There is a need for improved CCA biomarkers as currently used ones are suboptimal. Multiple staging systems have been developed, but none of these is optimal. The prognosis of CCA is considered dismal. However, treatment options have improved throughout the last two decades for carefully selected subgroups of CCA patients. Perihilar CCA can now be treated with orthotopic liver transplantation with neoadjuvant chemoradiation achieving 5-year survival rates of 68%. Classically considered chemotherapy-resistant, the ABC-02 trial has shown the therapeutic benefit of combination therapy with gemcitabine and cisplatin. The benefits of adjuvant treatments for resectable CCA, local ablative therapies and molecularly targeted therapies still need to be defined. In this article, we will provide the reader with an overview over CCA, and discuss the latest developments and controversies.Keywords
This publication has 98 references indexed in Scilit:
- Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinomaJournal of Surgical Oncology, 2014
- Proposal to modify the International Union Against Cancer staging system for perihilar cholangiocarcinomasBritish Journal of Surgery, 2013
- Classification, Diagnosis, and Management of CholangiocarcinomaClinical Gastroenterology and Hepatology, 2012
- Diabetes mellitus and increased risk of cholangiocarcinomaEuropean Journal of Cancer Prevention, 2012
- Management of hepatocellular carcinoma: An updateHepatology, 2011
- Liver transplantation for cholangiocarcinomaTransplant International, 2010
- Fluorescence in situ hybridization in diagnostic cytologyHuman Pathology, 2007
- [Four cases of hepatic fascioliasis mimicking cholangiocarcinoma].2005
- A Review and Update on CholangiocarcinomaOncology, 2004
- Intrahepatic cholangiocarcinoma: macroscopic type and stage classificationJournal of Hepato-Biliary-Pancreatic Surgery, 2003